Bharat Parenterals stock freezes at 5% upper circuit after receiving a license to manufacture Favipiravir

The product patent has been already filed under fast track approval, said Bharat Parenterals.

May 24, 2021 01:05 IST India Infoline News Service

Coronavirus
Bharat Parenterals has received the license and authorization from the Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of "FAVIPIRAVIR Oral Suspension 100mg/ml" which will be used for the treatment of Covid-19.

The company is the first one in the Indian Market to receive the license and authorization to manufacture and market FAVIPIRAVIR.

The product patent has been already filed under fast track approval, said Bharat Parenterals.

At around 1.37 PM, Bharat Parenterals was trading at the upper circuit of Rs406.20 per piece up by Rs19.30 or 4.99% on Sensex. 

Related Story

Open Free Demat Account (Rs699)